In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|August 18, 2026
ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine what actually drives the 6- to 12-month timeline reductions envisioned under Operation TrialBlazer, why trial modernization requires structural changes in sponsor-site collaboration, and a major biosimilars commercialization partnership.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part one of a new video interview , Amber Hill, PhD, founder and CEO of Research Grid, explained what hitting the six- to 12-month timeline reductions envisioned under Operation TrialBlazer actually demands operationally. AI-native automation can make the biggest difference earliest when focused on data standardization, site readiness, and early feasibility planning rather than on downstream activities where acceleration is limited by protocol constraints. - In a
new contributed article , Jim Reilly, president of Veeva Development Cloud, argued that faster, higher-quality trials require structural alignment in how sponsors, CROs, and sites plan and execute studies together. Earlier site engagement, shared visibility into study progress, role-based training, and connected technology platforms all work together to shift from fragmented handoffs toward collaborative partnership. Henlius Biotech entered a strategic collaboration with Sandoz covering up to 10 monoclonal antibody and antibody-drug conjugate biosimilar products for exclusive ex-China commercialization rights, with total financial consideration up to $322 million. The initial three partnered assets include proposed biosimilars for colorectal cancer, cholesterol management, and systemic lupus erythematosus (uh rith uh mi toe sis), with Sandoz incorporating commercial and market-access input into development and registration strategy from the outset.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5